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ABSTRACT 
The treatment of psychological diseases like schizophrenia has depended on the 
use of antipsychotic drugs many of which were created as far back as the 1970’s. 
These drugs typically act on the D2 dopamine receptor (D2R) to antagonize its 
signaling and alter the signaling of the mesolimbic and mesocortical dopaminergic 
pathways in the brain. Several studies have indicated that it may be more important to 
identify the specific receptor-protein interactions which could prove to be more 
beneficial drug targets for the treatment of schizophrenia (Magalhaes, Dunn, & 
Ferguson, 2012). In this study we identified that the fourth transmembrane motif in 
D2R is responsible for the receptor-protein interaction that was previously shown to 
decrease the detergent solubility of cellular Gβ5. Furthermore, we showed that the 
biophysical effects of this receptor-protein interaction could be significantly altered by 
treatment with clozapine but not haloperidol. Clozapine is a first generation 
antipsychotic that has been shown to have a unique efficacy for the treatment of 
schizophrenia compared to all other antipsychotics (Attard & Taylor, 2012). This 
finding identifies both a unique property of clozapine binding to the receptor and a 
significant alteration of receptor-protein interactions by a drug that previously was 
only thought to simply antagonize DA signaling at D2R.  
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CHAPTER 1 
 
INTRODUCTION 
 
Schizophrenia is a disease of the brain that is classically characterized by its 
positive, negative and cognitive symptoms.  The positive symptoms include delusions 
and hallucinations while negative symptoms refer to depressive symptoms and a 
general overall decrease in affect. Cognitively schizophrenia decreases the affected 
individuals ability to process information and to effectively utilize there working 
memory. Globally schizophrenia affects about 1% of the population and domestically 
about 1.2 % of Americans. This translates numerically to approximately 3.2 million 
Americans who need psychiatric care due schizophrenia (Nemade & Dombeck, 2009). 
The treatment of schizophrenia is most commonly accomplished via the antagonism of 
the D2 dopamine receptor (D2R) with the use of antipsychotic drugs (APD) (Stone & 
Pilowsky, 2007).  
D2R, the target of most APD is a G protein coupled receptor (GPCR) that signals 
within the cell by the activation of a heterotrimeric G protein consisting of a Gα and 
Gβγ subunits. Activation of D2R via the binding of dopamine catalyzes the transfer of 
a guanosine-5’-triphosphate (GTP) to the Gα subunit replacing a guanosine 
diphosphate, this causes the separation of the Gα subunit from the Gβγ subunit 
allowing them to signal independently of each other. D2 like receptors specifically 
activate Gαi/o proteins (Neve, Seamans, & Trantham-Davidson, 2004)(Bockaert & 
Pin, 1999). Gαi/o proteins compriseis a class of Gα proteins that is isare inactivated by 
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pertussis toxin; these proteins are considered to be inhibitory G proteins due to their 
inactivation of the adenylate cyclase causing a decrease in cAMP in the cell 
(Wettschureck & Offermanns, 2005).  
The other important signaling molecule released via the activation of D2R is the 
Gβγ subunit. Gβγ is able to affect its effectors usually located on the plasma 
membrane (PM) via protein-protein interactions. For example, Gβγ activates the 
inward rectifying potassium channel. The effectors that are modulated by the Gβγ 
subunit are diverse and determined by the specific isoforms of Gβ and Gγ subunits 
(Smrcka, 2008).  
The symptom alleviation by APD is thought to be due to the modulation of 
different pathways in the brain, specifically the dopaminergic pathways. Dysfunction 
of these pathways and associated symptoms include: the mesolimbic pathway 
associated with positive symptoms, the mesocortical pathway associated with negative 
symptoms, the nigrostriatal pathway associated with EPS and tardive dyskinesia and 
the tuberoinfundibular pathway associated with hyperprolactinemia (Beaulieu & 
Gainetdinov, 2011; Neve et al., 2004).  
There currently are two generations of APDs that both antagonise D2R. First 
generation (typical) antipsychotics are effective at relieving the positive symptoms of 
schizophrenia, but prolonged treatment leads to irreversible movement disorders 
collectively termed as extrapyramidal symptoms (EPS). These symptoms arise from 
binding to D2R expressed within the striatum, a region of the brain that is important 
for controlling movements. In the 1970s, a highly efficacious drug, clozapine, was 
introduced that suppresses both negative and positive schizophrenia symptoms.  It also 
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was found to have very low liability for producing movement disorders (Lieberman & 
Stroup, 2011).  Unfortunately, clozapine produced fatal agranulocytosis in about 1% 
of patients (Gerson & Meltzer, 2012).  It was found that clozapine,  has decreased 
affinity for D2R and increased affinity for the 5’hydroxytryptamine receptor (5HT 
receptor) compared to first-generation drugs, such as haloperidol.  Thus, it was 
hypothesized that the unique efficacy of clozapine was due to the differential 
pharmacological binding profile of clozapine compared to other antipsychotics. This 
encouraged drug companies to developed other molecules with similar 
pharmacological profile in the hope of producing drugs that recapitulated clozapine’s 
unique efficacy without producing agranulocytosis.  However, recent large-scale 
clinical studies with the second generation APD clearly demonstrated that second 
generation antipsychotics do not have the same clinical efficacy as clozapine in the 
treatment of schizophrenia (Attard & Taylor, 2012). 
In this thesis, I investigated the unique efficacy of clozapine in regards to the D2R 
and its receptor-protein interactions, which is supported by two initial findings in our 
lab. The first finding is that Gβ5 when co-expressed with D2R interacts with D2R in a 
manner that both stabilizes the proteins’ expression and moves it into a detergent 
resistant fraction (Octeau et al., 2014). Secondly, our lab has identified some unique 
properties of the drug clozapine as it relates to the binding of intracellular D2R. The 
findings show that APDs increase the detergent solubility of D2R, release of D2R 
from the endoplasmic reticulum (ER) and subsequently increase insertion of D2R into 
the plasma membrane. However, clozapine is unique in that it does not increase 
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receptor detergent solubility and has the smallest increase in plasma membrane 
insertion of D2R (Schrader, 2017). 
 My aim is to demonstrate that antipsychotic treatment is able to modulate the 
expression or solubility of Gβ5 as the result of antipsychotic binding of intracellular 
D2R. Furthermore, to determine the specific receptor-protein interaction between Gβ5 
and D2R as it relates to D2Rs’ ability to alter the biophysical properties of Gβ5 by 
determining the region of D2R that interacts with Gβ5.  Lastly, I will challenge how 
we classically think about the mechanism of APDs as they relate to the antagonism of 
D2R by showing another functional effect at the receptor that is not due to direct 
antagonism of receptor signaling and postulate a biochemical characteristic of D2R 
that has never previously been reported.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
Chemicals 
 Chemicals and reagents utilized in the following methods were obtained from 
Thermo Fisher Sceintific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO) unless 
otherwise noted. 
Cell Culture and Transfection 
 Cell Culture experiments were performed in HEK 293T cells obtained from 
American Type Culture Collection (ATCC CRL-3216). Cells were maintained 
according to the ATCC protocols using Dulbelcco’s modified Eagles media (DMEM) 
supplemented with penicillin (100 units/ml) and streptomycin (100 µg/ml) and 10% 
Fetal Bovine Serum (Sigma Aldrich) at 37°C and 5% CO2. Cell transfections were 
performed with complementary DNA (cDNA) using lipofectamine LTX reagent 
according to the manufacture’s instructions (LTX, Life Technologies). The cDNA 
constructs transfections were standardized between individual experiments by 
controlling the amount of cDNA transfected per well and by using the same 
expression vector for all constructs. 
 In experiments requiring drug treatment, 24 hours post transfection cells were 
treated with APDs at a 10 µM concentration for 24 hours. The two drugs utilized in 
this study were clozapine and haloperidol. 
cDNA Constructs 
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 The cDNA constructs used in all cell based experiments were created using 
standard molecular biology practices or obtained from other labs as cited. PCR was 
used to amplify, mutate, and add the desired sequences necessary to create the 
sequences needed for the constructs mentioned below. Amplified cDNA was inserted 
via ligation, following the protocols put forth by New England BioLabs, of PCR 
products into PCDNA 3.1+ Zeo, which is a mammalian expression vector allowing us 
to transiently express the desired proteins into mammalian cell lines (Thermo Fisher 
Scientific, 2016)(New England Bio Labs, 2016). PCR was carried out according to the 
specific conditions required by New England Bio lab’s (NEBs) for the TAQ 
polymerase to be used (New England Bio Labs, 2015). Constructs were validated via 
sequencing at the URI Genomic sequencing center funded by EpSCOR. 
 The following constructs were utilized for the completion of the mentioned 
experiments: N-terminally tagged FLAG D2 long (FLAG-D2R) (Glass & Felder, 
1997), Gβ5 short isoform construct (Kovoor et al., 2000), endoplasmic reticulum 
marker  mCh-Sec61 beta (Zurek, Sparks, & Voeltz, 2011), N-terminally FLAG-tagged 
mCherry linked to the D2R fourth transmembrane at the C terminus (D2-4tm 
mCherry), N-terminally FLAG-tagged  1st -3rd transmembrane of D2R(D2 1-3tm), N-
terminally FLAG-tagged  1st - fourth transmembrane of D2R(D2 1-4tm), FLAG-
D2RD114A (Mansour et al., 1992),  FLAG D2RW160A (Hanson et al., 2008),   FLAG 
D2RM155P(Nilsson et al., 1998). 
TX-100 cell lysate fractionation and total protein preparation 
 After transient expression of the protein into the HEK293-T cells, the cells 
were collected and lysed according to previously established protocols (Celver, 
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Sharma, & Kovoor, 2012). This procedure used a lysis buffer that contains 1X 
Phosphate buffered saline (PBS) and 2%(v/v) Triton-X 100 supplemented with a 
SigmaFast protease inhibitor diluted according to manufacturer specifications. Cells 
were lysed on ice for 1hr, followed by centrifugation at 10,000 g for 10 min to collect 
the TX-100 insoluble fraction. The soluble protein in the supernatant was then 
precipitated via a 10% w/v tri-chloroacetic acid precipitation. The protein was then 
pelleted and washed with ice cold 95% acetone 3X. Both pellets were then 
resuspended in a SDS sample buffer (2% (w/v) SDS, 50 mM Tris-HCl, 50 mM DTT, 
0.1% (w/v) bromphenol blue, pH 6.8) (Sharma, Celver, Octeau, & Kovoor, 2013). 
 For analysis of whole cell lysate, cells were collected in centrifuge tubes and 
washed once in 1X PBS. After washing in PBS the cell pellet was resuspended in SDS 
sample buffer and heated at 65°C for 10 min. After incubation the cells were sonicated 
10 x at a power setting of 5 for 0.5 seconds with 2 seconds between each pulse 
(XL2000-qSonica). Samples were then heated again post sonication at 65°C for 10 
min before being resolved on sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-Page) followed subsequently by western blotting for protein 
quantification. 
 
Western Blot Analysis 
  Protein samples were run on 10% SDS-Page gels and transferred to methanol 
activated PVDF membranes for antibody based detection. Post transfer the blots were 
blocked in 5% non-fat milk in PBS. Antibodies used were based on the protein of 
interest being targeted. Blots were probed with a FLAG-HRP conjugated antibody 
targeted against the FLAG tag (1:5000 in 10% nonfat milk in 1X PBS) (Sigma 
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Aldrich, 2016). The Gβ5 short isoforms were probed using the rabbit polyclonal 
antibody CT215 (1:5000 in 5%w/v nonfat milk in PBS)(Watson, Katz, & Simon, 
1994). Chemiluminescent signals from the HRP conjugated FLAG antibody and anti-
rabbit HRP conjugated secondary antibodies will be imaged using Supersignal West 
Femto substrate (Pierce-Thermo Fisher Scientific, n.d.) and detected using a 
Chemidoc XRS Molecular Imager (BIO-RAD, 2016). Images were converted to “.tif” 
files and analyzed using the ImageJ open source software (Schneider, Rasband, & 
Eliceiri, 2012). 
Immunocytochemistry 
Immunocytochemistry was performed on HEK293T cells that were cultured on 
poly-D-lysine coated cover slips. Cover slips were prepared by coating with poly-D-
lysine at a concentration of 50 µg/ml for 1 hr at 37°C, cover slips were then washed 3 
times in sterile PBS according to manufacture guidelines (Sigma). Prepared coverslips 
were placed into the bottom of 12-well plates and cells were then plated on top of 
them at a density of 1x105 cells/well, and transfected with the appropriate cDNA 
constructs. APD treatment of the cells occurred 24 hours post transfection. Cells were 
dosed at a final drug concentration of 10 µM.  
24 hours post drug treatment cells were fixed using ice cold 100% methanol to 
both fix and permeabilize the cells. Cells were washed 3x in 1X PBS, and blocked in 
5% (w/v in 1X PBS) nonfat milk for 1 hr at room temperature under constant 
agitation. Post blocking cells were probed with appropriate antibodies depending on 
the protein being identified. FLAG tagged proteins were identified by incubation in 
M2 Anti-FLAG (1:1000 dilution in 5% nonfat milk in 1X PBS) overnight at 4°C 
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under constant agitation (Sigma Aldrich, 2016, p. 2). Similarly the Gβ5 short isoforms 
were identified using the rabbit polyclonal antibody CT215 (1:1000 dilution in 5% 
nonfat milk in 1X PBS) under constant agitation (Watson et al., 1994). After overnight 
incubation in the primary antibody, cells were washed 2x with 1X PBS for 15 min at 
room temperature under constant agitation. The cells were then incubated for 1 hour at 
room temperature in appropriate Alexa Fluor conjugated secondary antibodies 
(1:5,000 dilution in 5% w/v Nonfat milk in 1X PBS) for imaging under fluorescent 
microscopy (Thermo Fisher Scientific, 2016). Microscopy was done with the use of a 
Zeiss LSM 700 confocal microscope, which was coupled to a HSP 120 metal halide 
lamp allowing for four excitation lines at 405, 488, 555, and 639. Microscopy also 
utilized the Zeiss Efficient Navigation (ZEN) Software for image processing and 
colocalization analysis. 
Data Analysis 
 Western blots were analyzed using ImageJ Software and area under the curve 
was determined for all necessary bands (Schneider et al., 2012). The values obtained 
from these analyses were then entered into Prism 7 for statistical analysis (GraphPad 
Prism 7, 2017). Values were first used to perform a one-way analysis of variance 
(ANOVA) if the P value obtained was <0.05 then a Tukey Post-hoc test was also 
performed to determine which groups were significantly different.  
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CHAPTER 3 
 
RESULTS 
 
Transiently expressed alone, Gβ5 solubility is unaffected by antipsychotic treatment. 
 Gβ5 transiently expressed alone into HEK293T cells was fractionated into 
detergent soluble and insoluble fractions. After western blot analysis it was 
determined that 72.16%± 4.88 was fractionated into the soluble fraction of the cell 
lysate, this repeated previously published data on the solubility of the transiently 
expressed receptor (Octeau et al., 2014). In order to determine if drug treatment alone 
was able to alter the solubility of Gβ5, transfected cells were treated for 24 hours with 
haloperidol and clozapine. Treatment with haloperidol and clozapine did not lead to 
any differences in the solubility of Gβ5 expressed in APD treated HEK293T cells 
indicating that drug treatment alone is not sufficient enough to cause an alteration of 
Gβ5 cellular detergent solubility (Fig. 1 A). 
Solubility of transiently expressed Gβ5 co-expressed with D2R is altered by 
clozapine treatment.  
 As previously reported, co-expression of Gβ5 with D2R causes Gβ5 to become 
more detergent insoluble, this effect was determined to be specific to a direct protein 
interaction with D2R and not through an regulatory of G protein signaling (RGS) 
intermediary (Octeau et al., 2014). The co-expression of D2R leads to percent 
detergent solubility of cellular Gβ5 to decrease from 72%± 4.88 (n=11) to 25%±5.00 
(n=12). After cells were treated with clozapine and haloperidol for 24 hours, the mean 
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percent solubility of Gβ5 in cells treated with clozapine increased, and was 
significantly different from both vehicle treated and haloperidol treated cells, which 
were not statistically different from each other (Figure 1A). While clozapine treatment 
increased total cellar Gβ5 solubility to 51%±5.00, it was also significantly different 
from cells transfected with only Gβ5. This result indicates that alteration of Gβ5 
detergent solubility is unique to clozapine is dependent on its co-expression with D2R.  
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Figure 1. Clozapine increases mean cellular Gβ5 detergent solubility in a D2R 
dependent manner. A) HEK293 cell were transiently transfected with Gβ5 and D2R 
+ Gβ5, cells were treated for 24 hours with APD and then separated into TX100 
soluble and insoluble fractions and reolved via SDS-PAGE used for western blotting 
and subsequent quantification. Bars represent the mean (n=9 ±S.E.M) solubility of 
Gβ5, bars not sharing a letter differ significantly at a P<0.05 (Tukey Post Hoc Test). 
B) Representative images from western blots depicting the relative levels of detergent 
soluble (S) and insoluble (I) Gβ5(upper panel) and total protein via coomasie blue 
staining (lower panel). 
Protein Stability of transiently expressed Gβ5 co-expressed with D2R. 
Co-expression of Gβ5 with D2R has been shown to also increase the protein 
stability of Gβ5 over time (Octeau et al., 2014). To determine if this effect of D2R on 
Gβ5 stability was also sensitive to treatment with an APD, HEK293T cells were co-
transfected with both Gβ5 and D2R and treated for 24 hrs with either clozapine or 
haloperidol at a final drug concentration of 10 µM. Figure 2 illustrates the mean 
increase of Gβ5 stability expressed as a of percent increase over cells expressing Gβ5 
alone. Results indicate that while co-expression of D2R did increase stability after 24 
hours, there was no statistical difference between cells treated with vehicle, clozapine 
and haloperidol.  
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Figure 2. Co-expression of Gβ5 with D2R increases Gβ5 stability, but stability is 
not significantly affected by treatment with APDs. A) HEK293 cell were 
transiently transfected with D2R + Gβ5, cells were treated for 24 hours with APD and 
then solubilized in SDS sample buffer and used for western blotting and subsequent 
quantification. Bars represent the mean (n=6 ±S.E.M) increase of Gβ5 signal 
expressed as a percent increase over cells expressing Gβ5 alone; bars not sharing a 
letter differ significantly at a P<0.05 (Tukey Post Hoc Test). B) Representative images 
from western blots depicting the relative levels of total Gβ5 signal (upper panel) and β 
actin signal (lower panel). 
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Gβ5 cellular distribution is altered when coexpressed with D2R and treated with 
haloperidol but not clozapine.  
It has been previously shown using immunocytochemistry (ICC) in HEK293T 
cells expressing D2R that treatment with haloperidol significantly alters the 
colocalization of D2R with the ER. This can visually be recognized by a clear increase 
in D2R signal at the PM after haloperidol treatment. Conversely no redistribution of 
D2R can be visualized after clozapine treatment and close to 90% of D2R instead is 
colocalized with the ER using a Sec 61 mCherry ER marker, indicating that clozapine 
is not altering cellular localization (Schrader, 2017; Zurek et al., 2011). In order to 
determine if this redistribution of D2R by haloperidol could also change the cellular 
distribution of Gβ5 we used immunocytochemistry to visually examine the 
distribution within the cell. Visually Gβ5 appears to mainly localize to the cytosol and 
is evenly distributed within the cell when expressed alone. When coexpressed with 
D2R and treated with haloperidol though, Gβ5 seems to visually redistribute within 
the cell. Under these conditions Gβ5 colocalizes more with D2R signal and shows a 
decrease in overall diffusion within the cytosol. Conversely treatment with clozapine 
does not visually alter the distribution of Gβ5 coexpressed with D2R (Figure 3). Drug 
treatment also was able to repeat previously reported results, which can be seen by the 
dramatic increase in PM D2R signal (Schrader, 2017). 
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Figure 3. Visual Gβ5 distribution is altered when coexpressed with D2R and 
treated with haloperidol but not clozapine. Green signal represents the signal from 
D2R labeled with the Alexa Fluor 488, red signal is from Gβ5 labeled with Alexa 
Fluor 568. Each column represents either D2R signal alone, Gβ5 signal alone, merged 
signal, or merged signal with the addition of transmitted signal used to illustrate the 
border of other cells within the image. Each row describes the transfected cDNA 
construct and treatment group. 
 17 
 
 Gβ5 detergent solubility is unaffected by APD when co-expressed with D2RD114A, 
Ligand binding deficient mutant. 
In order to determine if the clozapine induced alteration of Gβ5 detergent solubility by 
D2R is due to specifically to the binding of APD to D2R, a mutant D2R that is unable 
to bind antagonist was utilized. The D2R mutation was made in the binding pocket 
and was done by replacing an aspartic acid residue with an alanine residue at the 114 
amino acid position of D2R (Mansour et al., 1992).  D2RD114A upon co-expression was 
able to decrease Gβ5 solubility to 46%±4.82(n=6), but upon treatment with both 
haloperidol and clozapine no significant changes were seen in the mean detergent 
solubility of Gβ5 coexpressed with D2RD114A  (figure 4).  
 
 
Figure 4. Nonbinding mutant D2RD114A is able to decrease Gβ5 detergent 
solubility, this effect is unaltered by APD treatment. HEK293T cells transiently 
transfected with D2R nonbinding mutant D2RD114A and Gβ5, were treated for 24 hours 
with vehicle, clozapine or haloperidol. Cellular proteins were then fractionated into 
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TX100 soluble and insoluble fractions and run out on SDS-PAGE used for western 
blotting and subsequent quantification. Bars represent the mean (n=6 ±S.E.M) 
solubility of Gβ5, bars not sharing a letter differ significantly at a P<0.05(Tukey Post 
Hoc Test). 
Removal of D2R from the ER is important for the interaction of Gβ5 with D2R. 
 D2R when examined under confocal microscopy is often seen inside of the cell 
and not highly expressed on the PM. Furthermore a number of studies have identified 
ER retention signals within the 3rd intracellular loop of D2Rs protein sequence 
(Kubale, Blagotinšek, Nøhr, Eidne, & Vrecl, 2016). Furthermore, other studies have 
shown that a highly conserved tryptophan residue located in the fourth transmembrane 
across G protein coupled receptors (GPCR) that is important for cholesterol binding 
and interactions with other transmembrane domains and ultimately the trafficking of 
GPCRs within the cell (Dupré, Hébert, & Jockers, 2012; Hanson et al., 2008; 
Kobayashi, Ogawa, Yao, Lichtarge, & Bouvier, 2009). It has been previously shown 
that some molecules such are able to act as molecular chaperones, capable of 
stabilizing β-adrenergic receptor in a conformation that is able to overcome the 
tryptophan residue mutation and release it from the ER allow for dimerization of the 
mutated receptor (Kobayashi et al., 2009).  
We also have previously reported similar results with D2RW160A, a D2R mutant 
with a mutated tryptophan that is highly conserved across GPCRs (Schrader, 2017). 
This trafficking deficient D2RW160A was determined to be expressed exclusively in the 
ER of HEK293T cells by ICC colocalization with Sec61-mCherry ER marker. Rescue 
from the ER was accomplished via the treatment of haloperidol and observed by a 
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2000% increase in surface D2RW160A signal, however this increase in surface signal 
was not seen with the treatment of cells with clozapine. This suggests that haloperidol 
is able to act as a molecular chaperone within the cell, but clozapine binding of the 
receptor imparts a conformation that retains D2R within the ER (Schrader, 2017).  
In order to determine if the interaction of Gβ5 with D2R was occurring within 
the ER or in some intermediary between the ER and the PM we utilized the trafficking 
mutant D2RW160A. HEK293T cells were co-transfected with Gβ5 and D2RW160A, and 
dosed with 10 µM clozapine and haloperidol for 24 hrs. Cells were used for both ICC 
and TX-100 detergent fractionation and western blot quantification of detergent 
solubility.  Vehicle treated and clozapine treated cells expressing D2RW160A and Gβ5 
were unable to decrease the detergent solubility of Gβ5. Haloperidol treatment, which 
has previously been shown to release D2RW160A from the ER, was able to significantly 
decrease the detergent solubility of Gβ5 to 51%±3.96(n=6) compared to 82%±5.8 of 
vehicle treated cells (figure 5). Furthermore under ICC, Gβ5 appeared to be 
colocalized with D2RW160A signal (Figure 6). 
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Figure 5. D2R trafficking mutant, D2RW160A, is only able to effect Gβ5 detergent 
solubility after treatment with haloperidol. HEK293T cells transiently transfected 
with trafficking mutant D2RW160A and Gβ5, were treated for 24 hours with either 
vehicle, clozapine or haloperidol. Cellular proteins were then fractionated into TX100 
soluble and insoluble fractions and run out on SDS-PAGE used for western blotting 
and subsequent quantification. Bars represent the mean (n=6 ± S.E.M) solubility of 
Gβ5, bars not sharing a letter differ significantly at a P<0.05(Tukey Post Hoc Test). 
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Figure 6. Gβ5 distribution visualized by ICC is altered when coexpressed with 
D2RW160A and treated with haloperidol. Green signal represents the signal from 
D2RW160A labeled with the Alexa Fluor 488, red signal is from Gβ5 labeled with Alexa 
Fluor 568. Each column represents either D2RW160A signal alone, Gβ5 signal alone, 
merged signal, or merged signal with the addition of transmitted signal used to 
illustrate the border of other cells within the image. Each row describes the transfected 
cDNA construct and treatment group. 
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Identification of the D2R protein motif interacting with Gβ5. 
The ability of D2R to alter Gβ5 solubility has previously been determined to be 
due to a specific receptor-protein interaction (Octeau et al., 2014). It is important to try 
and understand the region of D2R where this interaction occurs, so that it can be 
determine if it might potentially be able to interact with other proteins as well or 
possibly be a target for drug compounds. D2R is a classic GPCR in that is made up of 
seven transmembrane regions. D2 differs from D1 type receptors due to a large 
intracellular third loop (Missale, Nash, Robinson, Jaber, & Caron, 1998). This large 
intracellular domain of D2R has been shown to interact with a number of proteins 
including calmodulin, β arrestins and calcium dependent protein kinase II (Fukunaga 
& Shioda, 2012).  
For this reason we assumed that is likely that the 3rd intracellular loop which is 
located between the fifth and sixth transmembrane domains of D2R is likely the region 
responsible for the interaction of D2R and Gβ5. We created a truncated version of 
D2R that specifically removed all amino acid residues after the end of the second 
extracellular loop. This truncation we called D2 1-4TM, expression of this receptor in 
HEK293T cells mimicked the detergent solubility of full length D2R and localization 
within the cell (data not shown). When D2 1-4TM was co-expressed with Gβ5 in 
HEK293T cells the truncated version of the receptor was still able to decrease the 
fraction of Gβ5 in the detergent soluble fraction (Figure 7 A) and was able to stabilize 
the expression of the Gβ5 after 24 hrs (figure 7 B).  
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Figure 7. The fourth transmembrane region of D2R is necessary for the 
alteration of both Gβ5 detergent solubility and protein stability. A) Protein from 
HEK293T cells transiently expressing Gβ5 and corresponding D2R variant cDNA 
construct as noted below each bar were fractionated into TX100 soluble and insoluble 
fractions and run out on SDS-PAGE used for western blotting and subsequent 
quantification. Bars represent the mean (n=6 ± S.E.M) solubility of Gβ5, bars not 
sharing a letter differ significantly at a P<0.05 (Tukey Post Hoc Test). B) Total protein 
from HEK293T cells transiently expressing Gβ5 and corresponding D2R variant 
cDNA construct as noted below each bar were resolved on SDS-PAGE used for 
western blotting and subsequent chemiluminescent quantification. Bars represent the 
mean (n=3 ±S.E.M) increase of Gβ5 signal expressed as a percent increase over cells 
expressing Gβ5 alone, bars not sharing a letter differ significantly at a P<0.05 (Tukey 
Post Hoc Test). C) Representative images from western blots depicting the relative 
levels of total Gβ5 signal (upper panel) and β actin signal (lower panel). 
 
 This was an interesting result, from previous publications we know that the 
fourth transmembrane of D2R is also responsible for a number of receptor-protein 
interactions usually described as dimerization and oligerimization with other receptors 
or homodimerization (Lee, O’Dowd, Rajaram, Nguyen, & George, 2003; Ng et al., 
1996; Scarselli et al., 2001). To determine if the fourth transmembrane might be 
responsible for interaction with Gβ5 we created another truncated version of D2R that 
removed the fourth transmembrane domain that we call D2 1-3TM. Co-expression of 
D2 1-3TM with Gβ5 in HEK293T cells did not cause a decrease in the fraction of 
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detergent soluble Gβ5. It also was unable to stabilize the expression of Gβ5 in 
HEK293T cells expressing D2 1-3TM. This indicates that the fourth transmembrane is 
important for imparting the decrease in the fraction of soluble Gβ5 and also to 
stabilization of Gβ5 expression in HEK293T cells (figure 7 A, B).  
To further explore this finding we created two more cDNA constructs. The first 
was a fusion protein of the fourth transmembrane of D2R that was attached to the C 
terminus of mCherry a red fluorescent protein. The second construct was a D2R 
mutant D2RM155P, is a D2R mutant that has a proline residue inserted into the alpha 
helix of the fourth transmembrane alpha helix causing it to misfold. This mutant has 
been previously shown to disrupt the topology of the fourth transmembrane and the 
ability of D2R to form homodimers (Lee et al., 2003).  
When expressed with Gβ5 the fusion construct 4 TM mCherry was able to both 
significantly decrease the fraction of soluble Gβ5 and stabilize the expression of Gβ5 
in HEK293T cells. Conversely, the misfolding mutant D2RM155P was not able to 
change the fraction of soluble Gβ5 and was not able to stabilize the expression of Gβ5 
(Figure 7 A,B). 
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CHAPTER 4 
 
DISCUSSION 
 
The importance of these findings is directly related to the antipsychotics used, the 
affects they had, and the identification of a specific region of D2R responsible for the 
receptor-protein interaction with Gβ5. I aimed to illustrate the ability of classic 
antipsychotic treatment to modulate a D2R receptor-protein interaction. We utilized 
the biophysical alteration of Gβ5 detergent solubility via the D2R-Gβ5 receptor-
protein interaction as the medium to demonstrate the ability of ADPs to alter receptor-
protein interaction. We were able to show that antipsychotics treatment modulated the 
detergent solubility of Gβ5 but were not able to significantly modulate the expression 
of Gβ5. 
What was interesting was the manner in which the ADP modulation occurred. 
D2R when expressed with Gβ5 is able to decrease the percent of Gβ5 present in the 
detergent soluble fraction. We know from immunocytochemistry(ICC) studies done 
(data not shown) and sequence analysis of D2R that the receptor is heavily retained 
within the ER by a number of protein motifs and that very small amounts of receptor 
is actually on the surface or in the secretory pathway on the way to the surface 
compared to total amounts of receptor present in the cell (Kubale et al., 2016; 
Schrader, 2017). Further, in figure 5 we show that the trafficking mutant D2RW160A, 
which previously has been shown to be completely retained in the ER, is unable to 
alter the percent solubility of Gβ5 when compared to cells expressing only Gβ5. But, 
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when treated with haloperidol, which we know releases D2RW160A from the ER, 
enables D2RW160A to alter the percent detergent solubility of Gβ5. This points to the 
interaction between the two proteins to be occurring outside of the ER where the 
smallest amount of total D2R receptor is located. We also know from figure 4 that 
Gβ5 detergent solubility is unchanged when coexpressed with a nonbinding mutant 
D2RD114A and when treated with haloperidol or clozapine, which means that any 
changes seen in figure 1 were in fact due to D2R binding by APDs.  
The ability of haloperidol to release D2RW160A from the ER indicates that it acts 
not only as an, antagonist of D2R but is also able to act as molecular chaperone able to 
change the conformation of the receptor in a way that enabled it to also interact with 
Gβ5. We also showed that clozapine treatment is able to increase the detergent 
solubility of Gβ5. This is interesting because from what we have determined so far 
there are only a couple of situations that allow for clozapine treatment to increase 
solubility. One possibility is that clozapine increases the retention of the receptor in 
the ER.  The other possibility is that the receptor when bound to clozapine is put into a 
conformation that inhibits the interaction of D2R and Gβ5. We have previously shown 
that while clozapine increases surface receptor the least, it still increases the insertion 
of D2R over that of vehicle treated which indicates that clozapine is not increasing the 
retention of D2R within the ER. This means that the conformation of D2R caused by 
the binding of D2R by clozapine is most likely a conformation that is not able to 
readily interact with Gβ5 in a manner that is able to alter the proteins detergent 
solubility.  
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We also performed experiments to try and investigate the region of D2R that 
might be interacting with Gβ5. Our ICC data indicates that Gβ5 is mostly cytosolic 
and does not appear to anchor itself within the plasma membrane. For this reason we 
first started by creating a D2R mutant that would remove the third intracellular loop 
(3rd ICL) of D2R. The 3rd ICL has previously been shown to interact with a number of 
proteins including the calmodulin and β arrestins (Ghanemi, 2015; Missale et al., 
1998). This approach proved unsuccessful, as the truncated D2 1-4TM was still able to 
decrease detergent solubility of Gβ5. We then continued by creating a construct that 
removed the fourth transmembrane region, this approach was successful as the new 
truncated D2 1-3 TM truncation was not able to decrease Gβ5 detergent solubility. We 
continued to test the hypothesis that it was the fourth transmembrane interacting with 
Gβ5 by using 4TM mCherry and D2RM155P. The fusion protein was able to decrease 
Gβ5 solubility while the 4 TM misfolding mutant D2RM155P was unable to 
significantly decrease the detergent solubility of Gβ5 as described in Figure 7. 
These results indicate the fourth transmembrane is important for the Gβ5-D2R 
protein-protein interaction. This is a bit of a confusing result as the fourth 
transmembrane of D2R should not be accessible to interaction with Gβ5 which ICC 
data shows to be mostly cytosolic, as D2R has been inserted into the plasma 
membrane. It is possible that the surface is exposed during transport to the surface 
membrane or that there is some other mediator acting between D2R and Gβ5. A 
protein mediator is unlikely to be the cause for a number of reasons. First, is that all 
RGS proteins expressed in HEK cells has previously been shown to be statistically 
insignificant due to there extremely low expression especially compared to the amount 
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transiently expressed Gβ5 (Atwood, Lopez, Wager-Miller, Mackie, & Straiker, 2011). 
Secondly the protein-protein interaction is able to occur both when the 4 TM is 
inserted in the membrane, which is the case for most of the truncations used and full 
length D2 receptors utilized in this study, but also when the 4TM is free in the cytosol 
which we see in the expression of the fusion protein 4TM mCherry. While improbable 
the data gained from both the misfolding mutant and D2R truncations suggest that at 
some point after exiting the ER the 4TM of D2R is assessable to Gβ5 and able to 
change the biophysical properties of Gβ5. 
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CHAPTER 5 
 
CONCLUSION 
 
 It is clear that D2R makes a protein-protein interaction with Gβ5 that results in 
a biophysical change in Gβ5. Most likely this change also alters Gβ5s’ ability to 
perform its normal cellular functions of inhibiting Gαi and Gαq mediated signaling 
with RGS7 (Witherow & Slepak, 2003). Furthermore, we were able to show that 
clozapine binding of the receptor invokes a conformation that is either unable to 
interact with Gβ5 causing its increased detergent solubility or localizes D2R in a place 
not assessable to Gβ5 interaction. These results illustrate another possible mechanism 
of GPCR signaling that is independent of dopamine(DA) activation of the receptor. 
The results show that APD, commonly classified as antagonists of D2R dopamine 
signaling, alter other D2R cellular consequences that are independent from DA 
signaling.   
 An increased awareness of protein-protein interactions and the effects that 
drugs have on them is needed (Magalhaes et al., 2012). There has been an increase in 
exploration into the “moonlighting” activities of many proteins that we classically 
think do one thing but recently have been discovered to also perform other of target 
actions. Similarly it is important to understand all protein interactions D2R is making 
and how different drugs might affect them. One theory that I would like to propose is 
that D2R has the ability to cause other proteins to become insoluble, which is due to 
its propensity to cause other proteins to aggregate. We know aggregated protein has 
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been associated with a number of diseases including Huntington’s and Alzheimer’s’. 
In these diseases soluble Tau and mutant Huntington protein act as prionogenic 
proteins, increasing the propensity for other proteins to aggregate (Brundin et al., 
2010). In figure 8 I propose a mechanism that explains how soluble D2R may act as a 
prionogenic protein which soluble form is able to interact with other proteins therefore 
causing them to aggregate. Furthermore the diagram illustrates how ER retention by 
clozapine could be neuro-protective preventing D2R from interacting and aggregating 
proteins in the cell. 
 
Figure 8. We propose D2R acts as a prionogenic protein and that this property is 
inhibited by clozapine.  The above diagram illustrates the ability for free soluble D2R 
in the right hand panel to freely interact with Gβ5 and cause it to aggregate inducing 
insolubility. The left hand panel illustrates clozapine binding of D2R increases ER 
retention of D2R and decrease the ability for D2R to interact with Gβ5, decreasing its’ 
prionogenicity.  
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